Bevacizumab in patients with previously treated metastatic colorectal cancer: preliminary results of a phase II study (bevacolor)

被引：0
作者：
Borg, C. [1 ]
Delord, J. P. [2 ]
Husseini, F. [3 ]
Lenoir, V. Trillet [4 ]
Faroux, R.
Francois, E. [5 ]
Ychou, M. [6 ]
Bergougnoux, L. [7 ]
Bennouna, J. [8 ]
Douillard, J. Y. [8 ]
机构：
[1] CHU Besancon, INSERM, U 645, Toulouse, France
[2] Inst Claudius Regaud, Toulouse, France
[3] Hop Louis Pasteur, Colmar, France
[4] Ctr Hosp Lyon Sud, Lyon, France
[5] Ctr Antoine Lacassagne, F-06054 Nice, France
[6] CHRU, Montpellier, France
[7] Dept Stat, Neuilly sur Seine, France
[8] Ctr Rene Gauducheau, F-44035 Nantes, France
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70998-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3070
引用
收藏
页码：257 / 257
页数：1
相关论文
共 50 条
  • [31] FOLFOXIRI plus bevacizumab (BEV) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Preliminary safety results from the OPAL study
    Stein, Alexander
    Atanackovic, Djordje
    Hildebrandt, Bert
    Stuebs, Patrick
    Steffens, Claus-Christoph
    Brugger, Wolfram
    Hapke, Gunnar
    Illerhaus, Gerald
    Bluemner, Ernst
    Bokemeyer, Carsten
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [32] A phase II study of dose-escalation of regorafenib for patients with previously treated metastatic colorectal cancer - DEREGULATE study - Trial in progress
    Kawaguchi, K.
    Nishitai, R.
    Manaka, D.
    Ota, T.
    Nishikawa, Y.
    Kudo, R.
    An, H.
    Hamasu, S.
    Konishi, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer
    Ryan, DP
    Clark, JW
    Kulke, MH
    Fuchs, CS
    Earle, CC
    Enzinger, PC
    Stuart, K
    Catarius, KJ
    Winkelmann, J
    Mayer, RJ
    CANCER INVESTIGATION, 2003, 21 (04) : 505 - 511
  • [34] Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium
    Sharma, Manish R.
    Wroblewski, Kristen
    Polite, Blase N.
    Knost, James A.
    Wallace, James A.
    Modi, Sanjiv
    Sleckman, Bethany G.
    Taber, David
    Vokes, Everett E.
    Stadler, Walter M.
    Kindler, Hedy L.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1211 - 1215
  • [35] Capecitabine (X), irinotecan (I) and bevacizumab (A) as first-line therapy for patients (PTS) with metastatic colorectal cancer (MCRC): Preliminary phase II study results
    Semir, Beslija
    Maja, Banjin
    Nadja, Paraganlija
    Timur, Ceric
    Anes, Pasic
    Berisa, Salkic
    Anes, Sosevic
    Nermina, Obralic
    ANNALS OF ONCOLOGY, 2006, 17 : 127 - 127
  • [36] Conditions on the use of bevacizumab in real life in patients with colorectal cancer treated in the first line metastatic: preliminary results of ETNA observational study
    Fourrier-Reglat, A.
    Ravaud, A.
    Smith, D.
    Jayles, D.
    Balestra, A.
    Grelaud, G.
    Rouyer, M.
    Moore, N.
    BULLETIN DU CANCER, 2009, 96 : S52 - S52
  • [37] A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer
    Hurwitz, H
    Fernando, N
    Yu, DH
    Morse, M
    Blobe, G
    Gockerman, J
    Odogwu, L
    Mahon, M
    Truax, R
    Franklin, A
    ANNALS OF ONCOLOGY, 2005, 16 : 285 - 285
  • [38] Phase II study of RAD001 in previously treated patients with metastatic pancreatic cancer
    Wolpin, B. M.
    Hezel, A. F.
    Ryan, D. P.
    Abrams, T. A.
    Meyerhardt, J. A.
    Blaszkowsky, L. S.
    Clark, J. W.
    Allen, B.
    Regan, E. M.
    Fuchs, C. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] Dasatinib (D) in previously treated metastatic colorectal cancer (mCRC) patients: A phase II trial of the University of Chicago phase II consortium
    Sharma, M.
    Wroblewski, K.
    Kozloff, M.
    Modi, S. S.
    Sleckman, B. G.
    Taber, D.
    Vokes, E. E.
    Stadler, W. M.
    Polite, B. N.
    Kindler, H. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [40] Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium
    Manish R. Sharma
    Kristen Wroblewski
    Blase N. Polite
    James A. Knost
    James A. Wallace
    Sanjiv Modi
    Bethany G. Sleckman
    David Taber
    Everett E. Vokes
    Walter M. Stadler
    Hedy L. Kindler
    Investigational New Drugs, 2012, 30 : 1211 - 1215
12345